INT Medical Issues Updated Terms of Reference for Board Nomination Committee

Bulletin Express
昨天

Shanghai INT Medical Instruments Co., Ltd. (INT Medical, SEHK: 01501) has published an updated Terms of Reference and Rules of Procedures for its Board Nomination Committee, effective upon Board approval on 27 March 2026.

The Nomination Committee will comprise at least three directors, with a majority designated as independent non-executive directors and chaired by an independent non-executive director or the Board chairman. At least one member must be of a different gender, reflecting the company’s commitment to board diversity.

Key responsibilities include: • Annual review of the Board’s structure, size, composition and diversity, maintaining a formal skills matrix. • Identification and recommendation of candidates for director and senior management roles, with explicit focus on experience, expertise and diversity. • Ongoing assessment of independent non-executive directors’ independence and the time commitment of all directors. • Development and oversight of succession planning for the Board chair and chief executive officer. • Monitoring corporate governance practices, director training, compliance, and the company’s adherence to the Hong Kong Listing Rules’ Corporate Governance Code.

The Committee is empowered to seek independent professional advice at the company’s expense and to access all required information from senior management. Regular meetings will be held at least once a year, with a quorum of two members, including one independent non-executive director; extraordinary meetings may be convened with three business days’ notice.

The chair of the Committee will attend the company’s annual general meeting to respond to shareholder queries related to nomination activities. All committee resolutions on director nominations require Board review before submission to shareholders for approval.

These rules supersede previous versions; any future amendments must be ratified by the Board and will default to prevailing PRC laws, the Hong Kong Listing Rules, and the company’s Articles of Association in case of conflict.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10